Literature DB >> 11042510

Pathogenesis of HIV-1 infection within bone marrow cells.

J Kulkosky1, M Bouhamdan, A Geist, G Nunnari, D G Phinney, R J Pomerantz.   

Abstract

Mononuclear phagocytic cells and CD4+ T lymphocytes represent the major targets for infection by HIV-1 in vivo. The most severe pathogenic features associated with HIV-1 infection can be attributed to malfunction or premature death of these cells that are of hematopoietic origin. Patients with acquired immunodeficiency syndrome (AIDS), suffer from many hematologic disorders, particularly those persons with long-term infection of HIV-1. These disorders include anemia, lymphocytopenia, thrombocytopenia and neutropenia. The mechanisms that lead to the induction of these disorders are multi-factorial. However, sufficient evidence has accumulated which suggests that HIV-1 infection of cells within the microenvironment of the bone marrow can lead to the induction of hematopoietic deficits. Most studies indicate that marrow-derived hematopoietic stem cells cannot be infected by HIV-1 until they undergo modest differentiation in order to express the appropriate receptors to enable virus entry and subsequent replication. Some cells within the mixed environment of the marrow stroma appear to support HIV-1 replication however. These cells include marrow microvascular endothelial cells, sometimes referred to as blanket cells, stromal fibroblasts, as well as mononuclear phagocytes. Our recent experiments suggest that the HIV-1 accessory protein, Vpr, plays some role in the activation of marrow-derived mononuclear phagocytes which appears to result in premature phagocytosis of non-adherent marrow cells present in the in vitro cultures. This phenomenon could account, in part, for the induction of cytopenias that are typical of individuals infected by HIV-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042510     DOI: 10.3109/10428190009058502

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Targeting and hematopoietic suppression of human CD34+ cells by measles virus.

Authors:  Marianne Manchester; Kent A Smith; Danelle S Eto; Hugh B Perkin; Bruce E Torbett
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 2.  HIV RNA suppression and immune restoration: can we do better?

Authors:  Marilia Rita Pinzone; Michelino Di Rosa; Bruno Cacopardo; Giuseppe Nunnari
Journal:  Clin Dev Immunol       Date:  2012-03-25

3.  Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.

Authors:  Yongjun Sui; Blake Frey; Yichuan Wang; Rolf Billeskov; Shweta Kulkarni; Katherine McKinnon; Tracy Rourke; Linda Fritts; Christopher J Miller; Jay A Berzofsky
Journal:  PLoS Pathog       Date:  2017-05-12       Impact factor: 6.823

4.  Unusual Signs and Symptoms in HIV-Positive Patients Coinfected with Leishmania spp: The Importance of Neglected Tropical Disease in Differential Diagnosis.

Authors:  Manuela Ceccarelli; Emmanuele Venanzi Rullo; Fabrizio Condorelli; Fabrizio Vitale; Vincenzo Di Marco; Giuseppe Nunnari; Giovanni Francesco Pellicanò
Journal:  Open Access Maced J Med Sci       Date:  2018-04-25

5.  Magnitude and associated factors of cytopenias among antiretroviral therapy naïve Human Immunodeficiency Virus infected adults in Dessie, Northeast Ethiopia.

Authors:  Zemenu Tamir; Abdurahaman Seid; Haftay Haileslassie
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.240

6.  Retrovirus-specificity of regulatory T cells is neither present nor required in preventing retrovirus-induced bone marrow immune pathology.

Authors:  Inês Antunes; Mauro Tolaini; Adrien Kissenpfennig; Michihiro Iwashiro; Kagemasa Kuribayashi; Bernard Malissen; Kim Hasenkrug; George Kassiotis
Journal:  Immunity       Date:  2008-11-14       Impact factor: 31.745

7.  Profile of HIV-Infected Hispanics with Pancytopenia.

Authors:  Eduardo J Santiago-Rodríguez; Angel M Mayor; Diana M Fernández-Santos; Robert F Hunter-Mellado
Journal:  Int J Environ Res Public Health       Date:  2015-12-22       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.